- META
- DB=ME66
- HITS=308333
- QUERY=TI=cancer
- OFFSET=1
- LIMIT=10
- AUTHOR=Pollack A
- CODEN=NYTIAO
- DB=MP_MEDLINE
- DBCOPYRIGHT=NLM
- DBRECORDID=ME17061339
- DOCTYPE=Newspaper Article
- ISSN=0362-4331
- KEY_CHEMTERM=Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; bevacizumab
- KEY_INDEXTERM=Genentech Inc.; Health Care and Public Health; Popular Approach/Source
- LANGUAGE=English
- MEDLINE_SUBUNIT=E
- MESH=ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL/*; ANTINEOPLASTIC AGENTS/adverse effects; ANTINEOPLASTIC AGENTS/*economics; ANTINEOPLASTIC AGENTS/*therapeutic use; BREAST NEOPLASMS/drug therapy; COLORECTAL NEOPLASMS/*drug therapy; DRUG COSTS/*; DRUG INDUSTRY/*economics; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; LUNG NEOPLASMS/*drug therapy
- MESH_GERMAN=ANGIOGENESE-INHIBITOREN; ANTIKÖRPER, MONOKLONALE/*; ANTITUMORMITTEL/unerwünschte Nebenwirkungen; ANTITUMORMITTEL/*Ökonomie; ANTITUMORMITTEL/*therapeutische Anwendung; MAMMATUMOREN, MENSCH/Arzneimitteltherapie; KOLOREKTALE TUMOREN/*Arzneimitteltherapie; ARZNEIMITTELKOSTEN/*; PHARMAZEUTISCHE INDUSTRIE/*Ökonomie; MENSCH; VERSICHERUNG, KRANKEN-, LEISTUNG; LUNGENTUMOREN/*Arzneimitteltherapie
- NOTE=KIE Bib: health care/economics; patient care/drugs
- PAGES=C2
- PUBLCOUNTRY=United States
- PUBLDATE=2006-10-12
- PUBLYEAR=2006
- RECNO=1
- SOURCE=The New York times
- TITLE=Genentech caps cost of cancer drug for some patients.
- URL=start=1&limit=1&format=FULL&database=ME66&userstatus=EXTERN_NOORDER&MP_GRIPSQUERY=ND=ME17061339
- MURL=-
- ABSTRACT=OBJECTIVES: To assess knowledge of oral and pharyngeal cancer (OPC) clinical signs and risk factors, the association between the risk factors and OPC, and the experience with OPC screening between newly diagnosed OPC patients and controls among a population of veterans in North Carolina. STUDY DESIGN: A case-control study with 31 OPC cases and 30 frequency-matched controls recruited from 2003 to 2004. Bivariate analysis using chi-square statistics and multivariate logistic regression was implemented to estimate the association with OPC. RESULTS: Only 34% of respondents knew 1 clinical sign and 4 or 5 risk factors for OPC. The lifetime accumulation of tobacco had a significant relationship with OPC (>20 pack-years; OR, 3.2; 95% CI, 1.01-10.3). Many respondents had not had an oral cancer examination within 3 years, mostly through ignorance. Most VA OPC patients were diagnosed by physicians, rather than by dentists. CONCLUSIONS: A considerable knowledge deficit on OPC was found among North Carolina veterans. Use of tobacco was a risk factor for OPC in this population.
- AUTHOR=Kim HY; Elter JR; Francis TG; Patton LL
- DB=MP_MEDLINE
- DBCOPYRIGHT=NLM
- DBRECORDID=ME17052639
- DOCTYPE=Journal Article
- INSTITUTION=Dental Research Institute, Seoul National University, Seoul, Korea.
- ISSN=1528-395X
- ISSUE=5
- LANGUAGE=English
- MEDLINE_SUBUNIT=D; IM
- MESH=AGE FACTORS; ALCOHOL DRINKING/adverse effects; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; EARLY DIAGNOSIS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MOUTH NEOPLASMS/*diagnosis; MOUTH NEOPLASMS/etiology; MOUTH NEOPLASMS/prevention & control; NORTH CAROLINA; OROPHARYNGEAL NEOPLASMS/*diagnosis; OROPHARYNGEAL NEOPLASMS/etiology; OROPHARYNGEAL NEOPLASMS/prevention & control; QUALITY OF LIFE; QUESTIONNAIRES; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.; RISK FACTORS; SMOKING/adverse effects; SOCIOECONOMIC FACTORS; VETERANS/*; VETERANS/psychology; VETERANS/statistics & numerical data
- MESH_GERMAN=ALTERSFAKTOREN; ALKOHOLGENUß/unerwünschte Nebenwirkungen; FALL-KONTROLL-STUDIEN; CHI-QUADRAT-VERTEILUNG; FRÜHDIAGNOSE; WISSEN, EINSTELLUNG, VERHALTEN (GESUNDHEIT); MENSCH; LOGISTISCHE MODELLE; MÄNNLICH; MENSCHEN IM MITTLEREN LEBENSALTER; MUNDTUMOREN/*Diagnose; MUNDTUMOREN/Ätiologie; MUNDTUMOREN/Verhütung & Bekämpfung; NORTH CAROLINA; OROPHARYNXTUMOREN/*Diagnose; OROPHARYNXTUMOREN/Ätiologie; OROPHARYNXTUMOREN/Verhütung & Bekämpfung; LEBENSQUALITÄT; FRAGEBOGEN; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, U.S. GOV'T, P.H.S; RISIKOFAKTOREN; RAUCHEN/unerwünschte Nebenwirkungen; SOZIALÖKONOMISCHE FAKTOREN; VETERANEN/*; VETERANEN/Psychologie; VETERANEN/Statistik & Zahlen
- PAGES=625-31
- PUBLCOUNTRY=United States
- PUBLDATE=2006-11
- PUBLYEAR=2006
- RECNO=2
- SOURCE=Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
- TITLE=Prevention and early detection of oral and pharyngeal cancer in veterans.
- VOLUME=102
- URL=start=1&limit=1&format=FULL&database=ME66&userstatus=EXTERN_NOORDER&MP_GRIPSQUERY=ND=ME17052639
- MURL=-
- ABSTRACT=This study was carried out to evaluate the loss of heterozygosity (LOH) and microsatellite instability (MSI) in breast cancer, in the 12p13.3 and 1p32 chromosomal regions where RAD52 and RAD54 genes are localized. Polymorphic markers D12S98, D12S1698 for RAD52 and D1S209, D1S411 for RAD54 were used. Relationships between LOH and clinicopathological parameters, i.e. tumor type and grade, patient's age, steroid receptors status and lymph node and distal metastases were assessed. For alleles frequency estimation 100 primary breast cancers were tested. DNA isolated from paraffin-embedded tissues and their matched blood samples were analyzed for PCR-based LOH and MSI by fluorescence-based DNA sequencing technology. In analyzed cases LOH was found in 14% and 11% of informative cases for D12S98 and D12S1698 markers, respectively and in 18% and 17% of informative cases for D1S209 and D1S411 markers, respectively. The highest frequency of MSI was identified at loci D12S98 (10%) and D1S209 (11%). Significant correlations between RAD52 and RAD54 regions with concomitant LOH and histological type and progesterone receptor status were observed. In the case of RAD54 further correlations with respect to tumor grade and the presence of distal metastases were noticed.
- AUTHOR=Nowacka-Zawisza M; Brys M; Hanna RM; Zadrozny M; Kulig A; Krajewska WM
- CODEN=PJUPE5
- DB=MP_MEDLINE
- DBCOPYRIGHT=NLM
- DBRECORDID=ME17019970
- DOCTYPE=Journal Article
- INSTITUTION=Department of Cytobiochemistry, University of Lódz.
- ISSN=1233-9687
- ISSUE=2
- KEY_CHEMTERM=DNA, Neoplasm; Nuclear Proteins; RAD52 protein, human; RAD54L protein, human; Rad52 DNA Repair and Recombination Protein
- LANGUAGE=English
- MEDLINE_SUBUNIT=IM
- MESH=ADULT; AGED; BREAST NEOPLASMS/*genetics; BREAST NEOPLASMS/metabolism; BREAST NEOPLASMS/pathology; CARCINOMA, DUCTAL, BREAST/*genetics; CARCINOMA, DUCTAL, BREAST/metabolism; CARCINOMA, DUCTAL, BREAST/secondary; CARCINOMA, LOBULAR/*genetics; CARCINOMA, LOBULAR/metabolism; CARCINOMA, LOBULAR/secondary; DNA, NEOPLASM/analysis; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY/*; MICROSATELLITE REPEATS/*; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS/*genetics; NUCLEAR PROTEINS/metabolism; POLYMERASE CHAIN REACTION; RAD52 DNA REPAIR AND RECOMBINATION PROTEIN/*genetics; RAD52 DNA REPAIR AND RECOMBINATION PROTEIN/metabolism; RESEARCH SUPPORT, NON-U.S. GOV'T; SEQUENCE ANALYSIS, DNA
- MESH_GERMAN=ERWACHSENER; ALTE MENSCHEN; MAMMATUMOREN, MENSCH/*Genetik; MAMMATUMOREN, MENSCH/Stoffwechsel; MAMMATUMOREN, MENSCH/Pathologie; KARZINOM, INFILTRIERENDES, DUKTALES/*Genetik; KARZINOM, INFILTRIERENDES, DUKTALES/Stoffwechsel; KARZINOM, INFILTRIERENDES, DUKTALES/Metastase; KARZINOM, LOBULÄRES/*Genetik; KARZINOM, LOBULÄRES/Stoffwechsel; KARZINOM, LOBULÄRES/Metastase; DNA, TUMOR-/Analyse; WEIBLICH; MENSCH; VERLUST DER HETEROZYGOTIE/*; MIKROSATELLITEN-WIEDERHOLUNGEN/*; MENSCHEN IM MITTLEREN LEBENSALTER; TUMORSTADIENEINTEILUNG; ZELLKERNPROTEINE/*Genetik; ZELLKERNPROTEINE/Stoffwechsel; POLYMERASE-KETTENREAKTION; RAD52-DNA-REPARATUR- UND REKOMBINATIONSPROTEIN/*Genetik; RAD52-DNA-REPARATUR- UND REKOMBINATIONSPROTEIN/Stoffwechsel; SUPPORT, NON-U.S. GOV'T; SEQUENZANALYSE, DNA-
- PAGES=83-9
- PUBLCOUNTRY=Poland
- PUBLDATE=2006
- PUBLYEAR=2006
- RECNO=3
- SOURCE=Polish journal of pathology : official journal of the Polish Society of Pathologists
- TITLE=Loss of heterozygosity and microsatellite instability at RAD52 and RAD54 loci in breast cancer.
- VOLUME=57
- URL=start=1&limit=1&format=FULL&database=ME66&userstatus=EXTERN_NOORDER&MP_GRIPSQUERY=ND=ME17019970
- MURL=-
- ABSTRACT=Although viewed with scepticism by the medical and scientific community, complementary and alternative medicine (CAM) is being used by about 50% of Australians. Integrative medicine is a holistic approach to cancer care, with some CAM of proven effectiveness being used as adjuvants to conventional medical treatments. However, there is little evidence of a systematic process of evaluation or dialogue between mainstream cancer medicine and CAM providers in Australia. Collaboration, guidance and support for relevant research in this area are needed. The key elements of a process of furthering integrative medicine include improving knowledge about CAM; addressing uncertainties about CAM efficacy and safety; improving communication about CAM between medical practitioners and patients, and between medical practitioners and CAM practitioners; introducing regulatory frameworks and credentialing of CAM practitioners; and addressing ethical issues.
- AUTHOR=Robotin MC; Penman AG
- CODEN=MJAUAJ
- DB=MP_MEDLINE
- DBCOPYRIGHT=NLM
- DBRECORDID=ME17014406
- DOCTYPE=Journal Article
- INSTITUTION=The Cancer Council New South Wales, Sydney, NSW, Australia. monicar@nswcc.org.au
- ISSN=0025-729X
- ISSUE=7
- LANGUAGE=English
- MEDLINE_SUBUNIT=IM
- MESH=AUSTRALIA; COMPLEMENTARY THERAPIES/*organization & administration; COMPLEMENTARY THERAPIES/standards; COOPERATIVE BEHAVIOR; DELIVERY OF HEALTH CARE, INTEGRATED/*organization & administration; ETHICS, MEDICAL; GOVERNMENT REGULATION; HOLISTIC HEALTH/*; HUMANS; INTERPROFESSIONAL RELATIONS; MEDICAL ONCOLOGY/*organization & administration; NEOPLASMS/*therapy; PHYSICIAN'S PRACTICE PATTERNS; SAFETY MANAGEMENT; TREATMENT OUTCOME; UNCERTAINTY
- MESH_GERMAN=AUSTRALIEN; KOMPLEMENTÄRE THERAPIEVERFAHREN/*Organisation & Verwaltung; KOMPLEMENTÄRE THERAPIEVERFAHREN/Standard; KOOPERATIVES VERHALTEN; GESUNDHEITSVERSORGUNG, INTEGRIERTE/*Organisation & Verwaltung; ETHIK, MEDIZINISCHE; STAATLICHE REGULIERUNG; GANZHEITSMEDIZIN/*; MENSCH; INTERPROFESSIONELLE BEZIEHUNGEN; MEDIZINISCHE ONKOLOGIE/*Organisation & Verwaltung; TUMOREN/*Therapie; ÄRZTLICHE HANDLUNGSMUSTER; SICHERHEITS-MANAGEMENT; BEHANDLUNGSERGEBNIS; UNSICHERHEIT
- PAGES=377-9
- PUBLCOUNTRY=Australia
- PUBLDATE=2006-10-02
- PUBLYEAR=2006
- RECNO=4
- SOURCE=The Medical journal of Australia
- TITLE=Integrating complementary therapies into mainstream cancer care: which way forward?
- VOLUME=185
- URL=start=1&limit=1&format=FULL&database=ME66&userstatus=EXTERN_NOORDER&MP_GRIPSQUERY=ND=ME17014406
- MURL=-
- ABSTRACT=INTRODUCTION: We retrospectively analyze our experience in conservative treatment for infiltrating advanced breast cancer before implementation of selective sentinel node biopsy, specially focusing on characteristics, incidence, treatment and evolution of local-regional recurrences, disease-free survival time, overall survival and patient's satisfaction. MATERIAL AND METHODS: From January 1984 to 31st December 1998, 739 female patients were operated in our institution, diagnosed as having infiltrating breast cancer. One hundred and eighty-eight patients (25.43%) received conservative treatment and they were followed up until December 2003. RESULTS: Average age when diagnosed was 50.42 years old (24-87 years). 53.19% of the patients were premenopausal. After a median follow-up of 129 months (60-198 months), 13 women (6.91%) presented local -regional recurrence and the disease-free time was 48.4 months (8-108 months). Global survival rate was 83.5% and disease free survival rate was 80.85%. CONCLUSIONS: The management of choice for early stage (I and II) infiltrating breast cancer is nowadays conservative, with a low local-regional recurrence rate and survival rate that are comparable to radical mastectomy, according to the literature. It's a safe and efficient method that let us preserve the breast with a good esthetical result. In selected cases, when a regional recurrence occurs, a second conservative management is possible with a good control of the disease, although the most widely accepted treatment in these cases is total mastectomy.
- AUTHOR=Mena Mateos A; García Villanueva A; Moreno Montes I; Collado Guirao MV; Rojo Blanco R
- DB=MP_MEDLINE
- DBCOPYRIGHT=NLM
- DBRECORDID=ME17005469
- DOCTYPE=Journal Article
- INSTITUTION=General and Digestive Tract Surgery Department, Breast Diseases Unit, University Hospital Ramón y Cajal, Madrid, Spain. antoniommimm@wanadoo.es
- ISSN=1699-048X
- ISSUE=9
- KEY_CHEMTERM=Antineoplastic Agents
- LANGUAGE=English
- MEDLINE_SUBUNIT=IM
- MESH=ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS/*mortality; BREAST NEOPLASMS/pathology; BREAST NEOPLASMS/*therapy; CARCINOMA, DUCTAL, BREAST/*mortality; CARCINOMA, DUCTAL, BREAST/secondary; CARCINOMA, DUCTAL, BREAST/*therapy; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY; MIDDLE AGED; PATIENT SATISFACTION; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME
- MESH_GERMAN=ERWACHSENER; ALTE MENSCHEN; ALTE MENSCHEN, 80 JAHRE UND ÄLTER; ANTITUMORMITTEL; MAMMATUMOREN, MENSCH/*Mortalität; MAMMATUMOREN, MENSCH/Pathologie; MAMMATUMOREN, MENSCH/*Therapie; KARZINOM, INFILTRIERENDES, DUKTALES/*Mortalität; KARZINOM, INFILTRIERENDES, DUKTALES/Metastase; KARZINOM, INFILTRIERENDES, DUKTALES/*Therapie; KOMBINIERTE THERAPIE; WEIBLICH; VERLAUFSSTUDIEN; MENSCH; MASTEKTOMIE; MENSCHEN IM MITTLEREN LEBENSALTER; PATIENTENZUFRIEDENHEIT; STRAHLENTHERAPIE, DOSIERUNG; RETROSPEKTIVE STUDIEN; ÜBERLEBENSZEITANALYSE; BEHANDLUNGSERGEBNIS
- PAGES=672-5
- PUBLCOUNTRY=Spain
- PUBLDATE=2006-09
- PUBLYEAR=2006
- RECNO=5
- SOURCE=Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
- TITLE=Conservative treatment for infiltrating breast cancer. Ten years follow-up experience.
- VOLUME=8
- URL=start=1&limit=1&format=FULL&database=ME66&userstatus=EXTERN_NOORDER&MP_GRIPSQUERY=ND=ME17005469
- MURL=-
- ABSTRACT=PURPOSE: The purpose of the present work is to evaluate Quality of Life in a group of colorectal cancer patients in advanced stages of their disease, along a standard chemotherapy treatment protocol, through the EORTC core questionnaire QLQ-C30 and the colorectal cancer module QLQ-CR38. These two questionnaires had previously been validated in our country. The present study has the novelty of its use during the chemotherapy treatment. MATERIALS AND METHODS: A consecutive sample of 44 colon o rectal cancer patients in stage IV, from an initial group of 46 patients who were addressed, have filled in the questionnaires, in three moments during their treatment process. Clinical and demographic data have also been recorded. Quality of Life scores and changes in them among the three assessments have been calculated. RESULTS: The quality of life scores of patients who have followed the treatment have been >70 points (100) in most dimensions, and has shown similar to the clinical data. Changes of >20 points in the quality of life scores during the treatment process appear in areas related to toxicity, fatigue and insomnia. Quality of life has been stable or has had small changes (between 10 and 20 points) in most dimensions. CONCLUSIONS: Quality of Life in the present sample has been good in general. The treatment has been administered to patients who could tolerate it adequately.
- AUTHOR=Arraras Urdaniz JI; Vera García R; Martínez Aguillo M; Manterola Burgaleta A; Arias de la Vega F; Salgado Pascual E
- DB=MP_MEDLINE
- DBCOPYRIGHT=NLM
- DBRECORDID=ME17005468
- DOCTYPE=Journal Article
- INSTITUTION=Servicios de Oncología Médica y Oncología Radioterápica, Hospital de Navarra, Pamplona, Navarra, Spain. jiarraras@correo.cop.es
- ISSN=1699-048X
- ISSUE=9
- LANGUAGE=English
- MEDLINE_SUBUNIT=IM
- MESH=ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS/*therapeutic use; COLORECTAL NEOPLASMS/*drug therapy; COLORECTAL NEOPLASMS/physiopathology; COLORECTAL NEOPLASMS/psychology; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE/*; QUESTIONNAIRES; RESEARCH SUPPORT, NON-U.S. GOV'T; SICKNESS IMPACT PROFILE
- MESH_GERMAN=ANTINEOPLASTISCHE KOMBINATIONSCHEMOTHERAPIE-PROTOKOLLE/*therapeutische Anwendung; KOLOREKTALE TUMOREN/*Arzneimitteltherapie; KOLOREKTALE TUMOREN/Pathophysiologie; KOLOREKTALE TUMOREN/Psychologie; WEIBLICH; MENSCH; MÄNNLICH; MENSCHEN IM MITTLEREN LEBENSALTER; LEBENSQUALITÄT/*; FRAGEBOGEN; SUPPORT, NON-U.S. GOV'T; SICKNESS IMPACT PROFILE
- PAGES=664-71
- PUBLCOUNTRY=Spain
- PUBLDATE=2006-09
- PUBLYEAR=2006
- RECNO=6
- SOURCE=Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
- TITLE=Quality of Life assessment through the EORTC questionnaires of colorectal cancer patients in advanced disease stages.
- VOLUME=8
- URL=start=1&limit=1&format=FULL&database=ME66&userstatus=EXTERN_NOORDER&MP_GRIPSQUERY=ND=ME17005468
- MURL=-
- ABSTRACT=Most human cancers derive from a single cell targeted by genetic and epigenetic alterations that initiate malignant transformation. Progressively, these early cancer cells give rise to different generations of daughter cells that accumulate additional mutations, acting in concert to drive the full neoplastic phenotype. As we have currently deciphered many of the gene pathways disrupted in cancer, our knowledge about the nature of the normal cells susceptible to transformation upon mutation has remained more elusive. Adult stem cells are those that show long-term replicative potential, together with the capacities of self-renewal and multi-lineage differentiation. These stem cell properties are tightly regulated in normal development, yet their alteration may be a critical issue for tumorigenesis. This concept has arisen from the striking degree of similarity noted between somatic stem cells and cancer cells, including the fundamental abilities to self-renew and differentiate. Given these shared attributes, it has been proposed that cancers are caused by transforming mutations occurring in tissue-specific stem cells. This hypothesis has been functionally supported by the observation that among all cancer cells within a particular tumor, only a minute cell fraction has the exclusive potential to regenerate the entire tumor cell population; these cells with stem-like properties have been termed cancer stem cells. Cancer stem cells can originate from mutation in normal somatic stem cells that deregulate their physiological programs. Alternatively, mutations may target more committed progenitor cells or even mature cells, which become reprogrammed to acquire stem-like functions. In any case, mutated genes should promote expansion of stem/progenitor cells, thus increasing their predisposition to cancer development by expanding self-renewal and pluripotency over their normal tendency towards relative quiescency and proper differentiation.
- AUTHOR=Martínez-Climent JA; Andreu EJ; Prosper F
- DB=MP_MEDLINE
- DBCOPYRIGHT=NLM
- DBRECORDID=ME17005467
- DOCTYPE=Journal Article; Review
- INSTITUTION=Division of Oncology, Center for Applied Medical Research University of Navarra, Pamplona, Spain. jamcliment@unav.es
- ISSN=1699-048X
- ISSUE=9
- KEY_CASNO=E.C. 2.7.7.-
- KEY_CHEMTERM=MicroRNAs; Telomerase/E.C. 2.7.7.-
- LANGUAGE=English
- MEDLINE_SUBUNIT=IM
- MESH=ANIMALS; CELL TRANSFORMATION, NEOPLASTIC/*; CELL TRANSFORMATION, NEOPLASTIC/genetics; GENES, TUMOR SUPPRESSOR; HUMANS; LEUKEMIA/genetics; LYMPHOMA/genetics; MICRORNAS; MUTATION; NEOPLASMS/genetics; NEOPLASMS/pathology; ONCOGENES; RESEARCH SUPPORT, NON-U.S. GOV'T; TELOMERASE; TELOMERE; TUMOR STEM CELLS/*; TUMOR STEM CELLS/cytology; TUMOR STEM CELLS/physiology
- MESH_GERMAN=TIER; ZELLTRANSFORMATION, NEOPLASTISCHE/*; ZELLTRANSFORMATION, NEOPLASTISCHE/Genetik; GENE, TUMORSUPPRESSOR-; MENSCH; LEUKÄMIE/Genetik; LYMPHOM/Genetik; MICRORNAS; MUTATION; TUMOREN/Genetik; TUMOREN/Pathologie; ONKOGENE; SUPPORT, NON-U.S. GOV'T; TELOMERASE; TELOMER; TUMORSTAMMZELLEN/*; TUMORSTAMMZELLEN/Zytologie; TUMORSTAMMZELLEN/Physiologie
- PAGES=647-63
- PUBLCOUNTRY=Spain
- PUBLDATE=2006-09
- PUBLYEAR=2006
- RECNO=7
- SOURCE=Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
- TITLE=Somatic stem cells and the origin of cancer.
- VOLUME=8
- URL=start=1&limit=1&format=FULL&database=ME66&userstatus=EXTERN_NOORDER&MP_GRIPSQUERY=ND=ME17005467
- MURL=-
- ABSTRACT=Chemotherapy and radiation are two important modalities for cancer treatment. Many agents in clinical used have the ability to induce DNA damage, however they may be highly cytotoxic as a secondary effect. Different mechanisms are involved both, in detection and repair of DNA damage. The modulation of these pathways, has a great impact on clinical outcome and is frequently responsible of therapeutic resistance. Therefore, pharmacological inhibition of DNA damage repair pathways has been explored as a useful strategy to enhance chemo and radiosensitivity, thus it could be used for reversing drug resistance. Different agents have shown excellent results in preclinical studies in combination with radiation or chemotherapy. Early phase clinical trials are now being carried out using different DNA repair inhibitors targeting several enzymes such as PARP, DNA-PK or MGMT.
- AUTHOR=Sánchez-Pérez I
- DB=MP_MEDLINE
- DBCOPYRIGHT=NLM
- DBRECORDID=ME17005466
- DOCTYPE=Journal Article; Review
- INSTITUTION=Instituto de Investigaciones Biomédicas del CSIC
- ISSN=1699-048X
- ISSUE=9
- KEY_CHEMTERM=Antineoplastic Agents; Enzyme Inhibitors
- LANGUAGE=English
- MEDLINE_SUBUNIT=IM
- MESH=ANIMALS; ANTINEOPLASTIC AGENTS/*therapeutic use; DNA REPAIR/*drug effects; ENZYME INHIBITORS/*therapeutic use; HUMANS; NEOPLASMS/*drug therapy; NEOPLASMS/enzymology; NEOPLASMS/genetics; RESEARCH SUPPORT, NON-U.S. GOV'T
- MESH_GERMAN=TIER; ANTITUMORMITTEL/*therapeutische Anwendung; DNA-REPARATUR/*Arzneimittelwirkungen; ENZYMINHIBITOREN/*therapeutische Anwendung; MENSCH; TUMOREN/*Arzneimitteltherapie; TUMOREN/Enzymologie; TUMOREN/Genetik; SUPPORT, NON-U.S. GOV'T
- PAGES=642-6
- PUBLCOUNTRY=Spain
- PUBLDATE=2006-09
- PUBLYEAR=2006
- RECNO=8
- SOURCE=Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
- TITLE=DNA repair inhibitors in cancer treatment.
- VOLUME=8
- URL=start=1&limit=1&format=FULL&database=ME66&userstatus=EXTERN_NOORDER&MP_GRIPSQUERY=ND=ME17005466
- MURL=-
- AUTHOR=Casas Fernández de Tejerina AM
- DB=MP_MEDLINE
- DBCOPYRIGHT=NLM
- DBRECORDID=ME17005464
- DOCTYPE=Journal Article
- INSTITUTION=Coordinadora Sección SEOM de Cuidados Continuos, Hospitales Universitarios Virgen del Rocío, Sevilla, Spain. anam.casas.sspa@juntadeandalucia.es
- ISSN=1699-048X
- ISSUE=9
- LANGUAGE=English
- MEDLINE_SUBUNIT=IM
- MESH=CONTINUITY OF PATIENT CARE/*; HUMANS; MEDICAL ONCOLOGY/*standards; NEOPLASMS/*therapy; PALLIATIVE CARE/*; SOCIETIES, MEDICAL; SPAIN
- MESH_GERMAN=KONTINUITÄT DER KRANKENBEHANDLUNG/*; MENSCH; MEDIZINISCHE ONKOLOGIE/*Standard; TUMOREN/*Therapie; PALLIATIVPFLEGE/*; GESELLSCHAFTEN, MEDIZINISCHE; SPANIEN
- PAGES=629-34
- PUBLCOUNTRY=Spain
- PUBLDATE=2006-09
- PUBLYEAR=2006
- RECNO=9
- SOURCE=Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
- TITLE=Symptom management, supportive and palliative care: the continuum of care in the cancer patient. The SEOM's continuing care section.
- VOLUME=8
- URL=start=1&limit=1&format=FULL&database=ME66&userstatus=EXTERN_NOORDER&MP_GRIPSQUERY=ND=ME17005464
- MURL=-
- AUTHOR=García Jordá E
- DB=MP_MEDLINE
- DBCOPYRIGHT=NLM
- DBRECORDID=ME17005463
- DOCTYPE=Journal Article
- INSTITUTION=Spanish National Association of the Health's Journalists (ANIS), Spain.
- ISSN=1699-048X
- ISSUE=9
- LANGUAGE=English
- MEDLINE_SUBUNIT=IM
- MESH=ANIMALS; BIOMEDICAL RESEARCH/*trends; HUMANS; MEDICAL ONCOLOGY/*trends; NEOPLASMS/epidemiology; NEOPLASMS/prevention & control
- MESH_GERMAN=TIER; BIOMEDIZINISCHE FORSCHUNG/*Trends; MENSCH; MEDIZINISCHE ONKOLOGIE/*Trends; TUMOREN/Epidemiologie; TUMOREN/Verhütung & Bekämpfung
- PAGES=627-8
- PUBLCOUNTRY=Spain
- PUBLDATE=2006-09
- PUBLYEAR=2006
- RECNO=10
- SOURCE=Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
- TITLE=Cancer and modernity.
- VOLUME=8
- URL=start=1&limit=1&format=FULL&database=ME66&userstatus=EXTERN_NOORDER&MP_GRIPSQUERY=ND=ME17005463
- MURL=-